Mushrooms for Lupus, RA, and MS: Research Across Conditions

Mushrooms & Autoimmune Disease

1 randomized human trial exists across all three conditions — and it missed its primary endpoint

A 65-patient, 24-week double-blind trial of Ganoderma lucidum with San Miao San in active rheumatoid arthritis found an ACR20 response of 15% versus 9.1% on placebo, a difference that was not statistically significant. Lupus and multiple sclerosis have no human trial at all.

Li et al., Arthritis & Rheumatism, 2007

15% vs 9.1%

ACR20 response, reishi + San Miao San vs placebo in 65 RA patients (Li 2007)

3 Pathways

blocked by Antcin K in RA synovial fibroblast cell studies (Achudhan 2021–2022)

0 Trials

in lupus or MS — both research streams stop at animal models

Li et al., Arthritis & Rheumatism, 2007

View as image ↗

Research on mushrooms and autoimmune disease spans three of the most common immune-mediated conditions: rheumatoid arthritis, lupus (systemic lupus erythematosus), and multiple sclerosis. Almost all of it is preclinical — cell studies and animal model experiments. There is one exception, and it matters more than any of the laboratory work: a double-blind, randomized, placebo-controlled trial of a reishi-containing formula in 65 people with active rheumatoid arthritis.^[9] That trial did not meet its primary endpoint. For lupus and multiple sclerosis, no human trial has been run at all.

That is the baseline, and it needs to be stated clearly before anything else, because the honest position sits between two tempting simplifications. It is not true that mushrooms are untested in autoimmune disease. It is also not true that any mushroom has been shown to help patients with these diagnoses.

What the preclinical research shows is nevertheless specific and mechanistically coherent. A compound called Antcin K, derived from Antrodia cinnamomea mushroom, has been studied in rheumatoid arthritis synovial cells across three consecutive papers by the same research team, each targeting a distinct mechanism of joint destruction. A 2022 animal study showed multiple mushroom species suppressing demyelination in a multiple sclerosis mouse model. Animal models of lupus have been used to study both Antrodia camphorata and reishi's effects on kidney inflammation and immune cell ratios. The mushroom research for these three conditions points in a direction, not a destination.

For context on how mushroom compounds interact with the immune system generally, the complete guide to mushroom beta-glucans and immunity covers the foundational mechanisms. This article covers what the condition-specific research shows for RA, MS, and lupus specifically.

Evidence Reach by Condition

Three Conditions, Three Different Altitudes

These three diseases are usually discussed as one research story. They are not at the same stage. Lupus and MS stop at animal models. Rheumatoid arthritis is the only one that has been tested in people — and that trial did not meet its primary endpoint. No condition has reached the top rung.

Rheumatoid arthritis

• Cells: Antcin K blocks TNF-α, IL-1β, IL-8 [3]; VCAM-1 adhesion [4]; VEGF angiogenesis [5]
• Animals: reishi nanogel, CFA rats [7]; GLPP, collagen-induced arthritis rats [13]
• Humans: 65 patients, 24 weeks — ACR20 15% vs 9.1% placebo, p > 0.05 [9]

Multiple sclerosis

• Cells / mechanism: neuroprotective and immunomodulatory pathways, review only [8]
• Animals: fruiting bodies suppress demyelination, cuprizone mice [6]
• Humans: no trial has been run

Lupus (SLE)

• Cells: antroquinonol cuts TNF-α 75%, IL-1β 78% in macrophages [1]
• Animals: nephritis attenuated, NZB/W F1 mice [1]; Treg ↑ / IL-17A ↓, MRL/lpr mice [11]
• Humans: no trial has been run

The single human trial [9] is the reason this article cannot be summarised as “entirely preclinical” — and the reason it also cannot be summarised as “mushrooms help autoimmune disease.” It was run, and it did not show a significant response benefit. Everything else on the chart is still in cells and animals.

Evidence synthesis; rungs from refs [1][3][4][5][6][7][8][9][11][12][13]

Why RA, Lupus, and MS Converge on the Same Immune Pathways

All three conditions involve the immune system attacking the body's own tissue. In rheumatoid arthritis, immune cells infiltrate the joints, releasing cytokines that destroy cartilage and bone. In multiple sclerosis, immune cells attack the myelin sheath that insulates nerve fibers, disrupting nerve signal transmission. In lupus, autoantibodies and immune complexes cause inflammation across multiple organ systems, including the kidneys, skin, and blood.

Despite the different target tissues, the immune pathways involved overlap substantially. All three conditions involve imbalances in specific immune cell populations. The ratio between regulatory T cells (which suppress immune activity) and Th17 cells (which drive pro-inflammatory responses) is dysregulated in each. Pro-inflammatory cytokines called TNF-α and IL-17 are elevated in all three. The molecules that allow immune cells to adhere to tissue walls and enter inflamed areas are overactivated in each.

This biological overlap is why research on mushroom compounds for one condition can be relevant to all three. A compound that reduces TNF-α in RA synovial cells is working on the same signaling molecule that drives tissue destruction in lupus and contributes to central nervous system inflammation in MS. This does not mean outcomes translate automatically across conditions, but it explains why the research literature often connects them.

For a deeper look at how mushrooms interact with immune system balance at the mechanistic level, the article on immunomodulation vs. immunostimulation for autoimmunity covers that framework in detail.

Rheumatoid Arthritis: One Mushroom Compound, Three Distinct Ways to Block Joint Destruction

The most coherent body of mushroom research for any specific autoimmune condition is the Antcin K series for rheumatoid arthritis. Three studies from Achudhan and colleagues, published between 2021 and 2022, systematically examined how a single mushroom compound affects the three main mechanisms by which RA destroys joints.

Antcin K is a triterpenoid compound extracted from Antrodia cinnamomea, a mushroom found primarily in Taiwan and studied extensively in Asian herbal medicine research. It is structurally similar to compounds from Antrodia camphorata, which has its own autoimmune research history.

Antcin K · Antrodia cinnamomea

One Compound, Three Separate Limbs of Joint Destruction

Rheumatoid arthritis destroys a joint through three different processes: inflammatory signalling, immune cell infiltration, and the new blood supply that feeds the invading tissue. Three consecutive papers from the same group tested Antcin K against each one. All three were cell-culture experiments in human RA synovial fibroblasts.

1. Cytokine output [3]

These three cytokines start the cascade, amplify joint damage, and call in more immune cells.

2. Immune cell adhesion [4]

VCAM-1 is the docking port monocytes use to enter joint tissue. Block it and they never arrive.

3. Blood vessel growth [5]

Inflamed synovium grows its own vessels to feed the pannus that invades cartilage and bone.

Mechanisms from refs [3][4][5] (Achudhan et al., 2021–2022)

The cytokine study. Achudhan and colleagues published the first paper in 2021 in Frontiers in Immunology, showing that Antcin K inhibited the production of TNF-α, IL-1β, and IL-8 in rheumatoid arthritis synovial fibroblasts.^[3] These three molecules are central drivers of RA pathology: TNF-α initiates the inflammatory cascade, IL-1β amplifies joint damage, and IL-8 recruits more immune cells to the joint space. The same study showed that Antcin K also reduced cartilage degradation, meaning the protective effect extended beyond cytokine signaling to actual preservation of joint tissue.

This combination of blocking inflammatory signals and protecting cartilage simultaneously is mechanistically significant. Most targeted RA therapies (biologics like anti-TNF drugs) address one pathway. A single natural compound showing effects on three pro-inflammatory cytokines plus direct cartilage protection in the same study represents an unusually broad preclinical profile.

The adhesion molecule study. The second Achudhan paper, published in Food & Nutrition Research in 2022, examined how Antcin K affects VCAM-1, an adhesion molecule on the surface of synovial fibroblasts.^[4] VCAM-1 functions like a docking port: monocytes (a type of immune cell that drives inflammation) bind to VCAM-1 on the synovial membrane and enter the joint tissue. Blocking this docking mechanism prevents inflammatory immune cells from infiltrating the joint in the first place.

Antcin K inhibited this VCAM-1-dependent monocyte adhesion process. This is a distinct mechanism from cytokine inhibition. Where the 2021 study blocked the signals that activate joint destruction, the 2022 adhesion study blocked the pathway by which destructive immune cells reach the joint tissue.

The angiogenesis study. The third study in the series, published in the Journal of Food Biochemistry in 2022, examined how Antcin K affects VEGF-driven angiogenesis in RA synovial tissue.^[5] In RA, the inflamed synovial tissue grows its own blood vessels (angiogenesis) to supply the expanding, destructive tissue. This growing tissue mass, called pannus, invades cartilage and bone. VEGF (vascular endothelial growth factor) is the signaling molecule that drives this vascular growth.

Antcin K inhibited VEGF-dependent angiogenesis in RA synovial fibroblasts. This third mechanism targets the structural expansion of the joint damage, not just the inflammatory signaling. Together, the three studies establish that Antcin K blocks the cytokine signals, the immune cell entry, and the vascular support that together enable RA pathology.

All three studies are in vitro (cell culture). No animal study and no clinical trial data exists for Antcin K in RA.

The One Human Trial: Reishi Plus San Miao San in Active RA

Rheumatoid arthritis is the only one of these three conditions that has been taken into a randomized human trial. Li and colleagues published that trial in Arthritis & Rheumatism in 2007.^[9]

The Only Randomized Trial

Li, Tam, Wong et al. (2007) · Arthritis & Rheumatism

Population

65 adults with active RA despite disease-modifying antirheumatic drugs (32 treatment, 33 placebo)

Intervention

Ganoderma lucidum 4 g + San Miao San 2.4 g daily for 24 weeks, added to existing medication

Comparator

Matched placebo added to existing medication

Finding

ACR20 response was 15% in the treatment group versus 9.1% on placebo, which was not statistically significant. Pain score and patient's global score improved significantly within the treatment arm only. Plasma cytokines, lymphocyte counts and oxidative stress markers were unchanged.

mixed Primary endpoint not met. The authors concluded the combination may have analgesic effects and was generally safe, but no significant antioxidant, anti-inflammatory or immunomodulating effect could be demonstrated.

Li EK, et al. Arthritis Rheum. 2007;57(7):1143-50.

The One Human Trial

What Actually Moved in 65 Patients Over 24 Weeks

Reishi plus San Miao San was tested against placebo in people with active rheumatoid arthritis, on top of their existing disease-modifying drugs. Reading only the pain result makes it look positive. Reading only the primary endpoint makes it look negative. Both columns are the trial.

Trial design [9]

Double-blind, randomised, placebo-controlled pilot trial. 32 patients assigned to Ganoderma lucidum 4 g + San Miao San 2.4 g daily, 33 to placebo, both in addition to existing DMARDs. 24 weeks. 89% completed. Note that this is a two-herb combination, not reishi alone — no arm isolated the mushroom.

The authors’ own conclusion is the fairest summary: the combination “may have analgesic effects for patients with active RA, and were generally safe and well tolerated. However, no significant antioxidant, antiinflammatory, or immunomodulating effects could be demonstrated” [9]. A pilot trial this size can miss a real but modest effect — which is an argument for a larger trial, not a substitute for one.

Li 2007, Arthritis & Rheumatism [9]; Bao 2006 [10]

Three things about this trial deserve emphasis, because it is routinely cited in both directions.

First, it tested a combination, not reishi by itself. San Miao San is a three-herb traditional formula (Rhizoma atractylodis, Cortex phellodendri, Radix achyranthes bidentatae). No arm isolated the mushroom, so nothing in the result can be attributed to Ganoderma lucidum specifically.

Second, the primary endpoint failed. ACR20 — the standard measure of a 20% improvement in rheumatoid arthritis disease activity — was reached by 15% of the treatment group and 9.1% of placebo, and that gap did not reach statistical significance. A pilot trial of 65 people is small enough that a real but modest benefit could hide inside that result, which is an argument for running a larger trial rather than a reason to treat the question as settled either way.

Third, the immunological story is narrower than it is often reported. A companion paper from the same research group reported that plasma concentrations of IL-18 and a panel of other cytokines and chemokines were unchanged after 8 and 24 weeks of supplementation.^[10] What did differ was the percentage change in ex vivo-induced IL-18 — that is, IL-18 produced by the patients' cells when stimulated in the laboratory, not IL-18 circulating in their blood. That is a genuine signal, and it is a much smaller claim than "reishi lowers inflammation in RA patients."

Beyond the Antcin K series and this trial, two animal studies extend the reishi RA picture. Ratnaningtyas and colleagues published a 2024 study on a reishi nanogel formulation in a rat model of RA.^[7] The nanogel format was designed to improve delivery of reishi bioactives to joint tissue, and the study showed anti-arthritic, anti-inflammatory, and antioxidative activity in rats given the CFA (Complete Freund's Adjuvant) model of arthritis, a standard preclinical inflammation paradigm. Separately, Meng and colleagues reported in 2023 that a Ganoderma lucidum polysaccharide peptide reduced arthritis in collagen-induced arthritis rats given 100 or 200 mg/kg orally for 35 days, working through inactivation of the NF-κB and MAPK signaling pathways.^[13]

For readers interested in how cytokine profiles are targeted by mushroom compounds more broadly, the article on medicinal mushrooms and cytokine balance covers the landscape across conditions.

Multiple Sclerosis: Demyelination Suppression in a Mouse Model, Then a 2025 Review

Research on medicinal mushrooms and multiple sclerosis is newer than the RA research, and it has not reached human testing. Two publications anchor the current state of evidence: a 2022 animal study on demyelination and a 2025 review of the landscape.

The Yamashina 2022 study. Yamashina and colleagues published a study in the International Journal of Medicinal Mushrooms in 2022 examining whether medicinal mushroom fruiting bodies could suppress demyelination in a cuprizone-induced MS mouse model.^[6]

Cuprizone is a chemical compound that selectively destroys myelin in mice. When fed cuprizone, mice develop a demyelination pattern that resembles some aspects of MS pathology, and the model is widely used to study myelin repair and neuroprotection. Yamashina's team administered fruiting bodies from multiple medicinal mushroom species to cuprizone-treated mice and measured both myelin preservation and motor function.

The results showed that several mushroom species suppressed demyelination and reduced motor dysfunction compared to the cuprizone-only group. The study did not isolate a single compound or mechanism, but established that fruiting bodies from commonly available medicinal mushrooms could affect the myelin damage process in this model.

This is the first direct preclinical evidence that medicinal mushrooms may have myelin-protective properties in an MS context. It is animal model data, and the cuprizone model captures only some features of human MS, which has a more complex immune-mediated etiology. The finding is a starting point, not a clinical conclusion.

The Pourmohammadi 2025 review. Pourmohammadi and Moghimi published a review in Fitoterapia in 2025 synthesizing evidence on medicinal mushrooms as a "new approach" for managing MS.^[8] The review identified neuroprotective effects, anti-inflammatory mechanisms, and immunomodulatory properties in multiple mushroom species as potentially relevant to MS pathology. It is the most current overview of where the mushroom-MS research stands.

A review synthesizes existing work rather than generating new data, so it raises the visibility of this research area without raising its evidence level. The fact that a 2025 peer-reviewed review positioned mushrooms as a "new approach" for MS management reflects that the research community is beginning to take the mechanism seriously enough to organize it. The practical implication for patients is considerably less clear: the gap between preclinical mechanism data and established clinical therapy is substantial, and MS remains one of the hardest autoimmune conditions to develop new treatments for.

For the broader immunological mechanisms involved, the article on mushrooms and adaptive immunity explains how mushroom compounds interact with the T-cell populations central to MS pathology.

Lupus: A Kidney Inflammation Study and an Immune Ratio Shift From a Reishi Formula

Lupus research with medicinal mushrooms has produced two specific lines of preclinical evidence: one focused on organ protection (specifically the kidneys), and one focused on the immune cell ratio imbalance that drives lupus activity. Both are animal studies.

The Antrodia camphorata lupus nephritis study. Chang and colleagues published a 2011 study examining whether a mycelial extract of Antrodia camphorata could attenuate lupus nephritis in NZB/W F1 mice.^[1] The NZB/W F1 mouse is a lupus-prone hybrid strain that spontaneously develops lupus-like disease, including kidney inflammation (lupus nephritis). It is one of the most widely used lupus animal models because the disease progression resembles human lupus more closely than toxin-induced models.

The design is worth stating precisely, because the dose mattered. After antibodies against double-stranded DNA had appeared in the mice, the animals received the extract by gavage at 100, 200, or 400 mg/kg, five days per week, for 12 weeks. Only the 400 mg/kg dose significantly suppressed urine protein and serum blood urea nitrogen and reduced thickening of the kidney glomerular basement membrane. The two lower doses did not produce that effect. The same paper reported that antroquinonol, an active component of the extract, inhibited TNF-α and IL-1β production by 75% and 78% respectively in stimulated macrophage cell culture.

Lupus nephritis is one of the most serious complications of the disease; severe nephritis is a major driver of lupus-related organ damage and mortality. A study showing that a mushroom extract slows its progression in a relevant animal model represents a specific, clinically meaningful finding at the preclinical level — with the caveat that it took the highest of three tested doses to get there.

Antrodia camphorata is closely related to Antrodia cinnamomea, the source of Antcin K in the RA studies above. Both are Taiwan-endemic species in the same genus, and both show anti-inflammatory effects in autoimmune contexts, which gives the research a degree of internal consistency.

A reishi formula and the Treg/Th17 shift. Cai and colleagues published a 2016 study in Chinese Medicine testing a combination of Ganoderma lucidum and San Miao San (the same LZ-SMS formula later trialed in RA patients) in MRL/lpr mice, a second widely used lupus model.^[11]

The results were consistent across several measures. Plasma anti-double-stranded-DNA antibody concentrations fell significantly in treated moderate and severe lupus mice. The percentage of CD4+CD25+Foxp3+ regulatory T cells rose significantly in spleen, thymus, and peripheral blood, as did IL-10-producing regulatory B cells. The ratio of regulatory T cells to effector T cells increased significantly. Concentrations of IL-17A, IL-21, and IL-10 decreased. The clinical characteristics of the treated lupus mice improved.

The reishi literature is often summarized as showing "immune rebalancing rather than immune suppression," and the Cai data is the strongest single support for that framing. Bhardwaj and colleagues' 2014 review of Ganoderma lucidum pharmacology makes the broader case that this mushroom possesses immune-modulating and immune-potentiating capabilities relevant to chronic inflammatory and autoimmune conditions including lupus and rheumatoid arthritis.^[2] That review is a synthesis of mechanism and patent literature, not a source of new patient data.

For readers with lupus specifically concerned about kidney involvement, the article on Fu Ling and kidney inflammation covers a different mushroom species with nephroprotective evidence.

What These Three Research Streams Share: A Convergent Mechanism

The RA, MS, and lupus research streams converge on a common immunological target even though the conditions involve different tissues and different autoimmune mechanisms.

Across all three conditions, the mushroom compounds studied work through regulation of pro-inflammatory cytokines (primarily TNF-α and IL-17), modulation of immune cell populations (specifically Th17 and Treg balance), and interference with pathological tissue processes (angiogenesis in RA, demyelination in MS, kidney inflammation in lupus). The same compounds tend to appear across the research: Antrodia species and reishi show up in both RA and lupus research. Beta-glucan-rich mushrooms appear in the MS data.

Two studies outside the three condition-specific streams make the convergence concrete. Li and colleagues reported in 2015 that an Antrodia cinnamomea extract inhibited Th17 cell differentiation and the production of IL-17A, IL-21, and IL-22, an effect associated with inhibition of STAT3 phosphorylation and RORγt expression, and that oral administration reduced inflammation in a psoriasis mouse model.^[12] That is the same genus implicated in the RA and lupus work, acting on the same Th17 axis, in a fourth autoimmune condition. On the Ganoderma side, the 2023 collagen-induced arthritis study attributed its effect specifically to inactivation of NF-κB and MAPK signaling.^[13]

This convergence is mechanistically plausible. The molecular pathways involved in autoimmune inflammation, especially the NF-κB pathway that drives cytokine production, are shared across conditions. Compounds that inhibit NF-κB signaling would be expected to show effects across multiple autoimmune contexts. What convergent mechanism does not establish is convergent benefit: the RA trial that actually tested this idea in people did not show a significant response advantage.

For readers interested in the T-cell differentiation angle specifically, the article on mushroom polysaccharides and T-cell differentiation explains how beta-glucans interact with the Th17/Treg balance that is dysregulated in all three conditions. The article on mushrooms for autoimmune disease and immune balancing covers how the same compound can simultaneously activate underactive immunity and calm overactive immunity, which is the core pharmacological question for autoimmune patients.

The Evidence Ceiling: One Trial, and It Was Not Positive

The mechanistic coherence of this research area makes it easy to overstate the current evidence. With one exception, every study covered in this article is preclinical, meaning the studies used cell cultures, animal models, or both.

Fact Check

Does mechanism in the lab predict benefit in patients?

The claim

“Mushroom compounds block the exact pathways that drive RA, lupus, and MS — so they should help people with those diseases.”

The preclinical results are genuinely strong and internally consistent, which makes the leap to patients feel small.

What research shows

Overstated

The leap was actually tested once. A reishi-containing formula was given to 65 people with active RA for 24 weeks in a double-blind, placebo-controlled trial, and the ACR20 response rate was 15% versus 9.1% on placebo — not statistically significant. Plasma cytokines and lymphocyte counts did not change.

This does not prove mushrooms are useless in autoimmune disease. A 65-person pilot can miss a modest real effect, the trial tested a combination rather than an isolated compound, and pain and patient global scores did improve within the treatment arm. But it does show that convergent mechanism data is not a substitute for outcome data.

Li EK, et al. Arthritis Rheum. 2007;57(7):1143-50 [9]

The Antcin K RA studies are in vitro. Synovial fibroblasts in a culture dish are not joints in a human body. Real RA involves complex interactions between multiple cell types, systemic inflammation, and years of progressive damage. A compound that inhibits three cytokines in cultured cells may not reach the same concentrations in joint tissue after oral administration. It may not persist long enough to be effective. The metabolites produced when the body processes the compound may be more or less active than the compound itself.

The Yamashina MS mouse model used cuprizone-induced demyelination, which causes myelin loss through a toxic mechanism rather than an immune-mediated one. Human MS is primarily an immune-mediated disease. What works in cuprizone mice may not work in MS patients for this reason.

The lupus mouse models (NZB/W F1 for nephritis, MRL/lpr for the Treg/Th17 data) are more clinically relevant to human lupus than cuprizone is to MS, but still limited. Human lupus is more heterogeneous and more complex than any mouse model captures. Both lupus studies also used doses and delivery routes that have no established human equivalent — 400 mg/kg by gavage in mice does not translate to a capsule dose in people.

None of this invalidates the research. Preclinical data is how pharmaceutical development begins. The specificity of the Antcin K findings, the coherent three-pathway RA profile, and the myelin protection in Yamashina's multi-species study are meaningful signals worth taking seriously. They are not yet clinical conclusions, and the one time this line of reasoning was carried into a randomized trial, the primary endpoint was missed.

Before You Act On This

Moderate

Autoimmune patients on immunosuppressive therapy

Concern

People with RA, lupus, and MS are frequently on DMARDs, corticosteroids, biologics, or other immunosuppressive drugs. Mushroom supplements marketed for 'immune support' are generally formulated to stimulate immune activity, which is the opposite of what these medications are prescribed to do. No mushroom product has been shown to be safe alongside these therapies, and no mushroom product has been shown to help these diseases.

What the research says

The only randomized trial in this article added its formula on top of existing DMARDs rather than replacing them, and reported that it was generally well tolerated: 22 mild adverse events across 13 patients, with more events in the placebo arm (14) than the treatment arm (8). That is reassuring about short-term tolerability in one specific combination at one specific dose — it is not a general safety clearance for mushroom supplements in autoimmune disease.

Particularly relevant for: Anyone with RA, lupus, MS, or another autoimmune diagnosis, particularly those on immunosuppressive or immunomodulating medication

What to do

Nothing in this article is medical advice, and none of it should be used to start, stop, or change a treatment. Disclose any supplement you are taking or considering to the specialist managing your condition, because interactions with immunosuppressive therapy have not been characterized.

Li EK, et al. Arthritis Rheum. 2007;57(7):1143-50 [9]

The article on mushrooms and autoimmune disease covers the safety considerations for patients navigating this uncertainty. The article on mushroom supplement safety for autoimmune patients addresses the practical risk questions directly.

The Bottom Line

Research on medicinal mushrooms across rheumatoid arthritis, lupus, and multiple sclerosis is almost entirely preclinical, with one exception. A double-blind, randomized, placebo-controlled trial gave Ganoderma lucidum plus San Miao San to 65 people with active RA for 24 weeks; the ACR20 response was 15% versus 9.1% on placebo, which was not statistically significant, though pain and patient global scores improved within the treatment arm and the formula was well tolerated. The laboratory work is more encouraging: Antcin K from Antrodia cinnamomea blocked three distinct mechanisms of joint destruction in consecutive cell studies, and reishi preparations showed anti-arthritic effects in two rat models. For MS, a 2022 animal study established myelin-protective effects from multiple mushroom species, with a 2025 review synthesizing the mechanistic landscape. For lupus, animal data shows kidney inflammation attenuation from Antrodia camphorata mycelial extract at 400 mg/kg and Treg increases with IL-17A decreases from a reishi-containing formula. No human trial has been conducted in lupus or multiple sclerosis.

Frequently Asked Questions

Has any mushroom been tested in a human trial for autoimmune disease?

Yes, once. A 2007 double-blind, randomized, placebo-controlled pilot trial gave Ganoderma lucidum (4 g) plus San Miao San (2.4 g) daily for 24 weeks to 32 people with active rheumatoid arthritis, with 33 on placebo, in addition to their existing disease-modifying drugs. The primary endpoint, ACR20 response, was 15% in the treatment group versus 9.1% on placebo, a difference that was not statistically significant. Pain and patient global scores improved within the treatment arm, and the formula was generally safe and well tolerated. The authors concluded it may have analgesic effects but that no significant antioxidant, anti-inflammatory, or immunomodulating effects could be demonstrated. No comparable trial exists for lupus or multiple sclerosis.

What does research show about mushrooms and rheumatoid arthritis?

The strongest laboratory body of work covers Antcin K, a triterpenoid from Antrodia cinnamomea. Three consecutive studies showed that Antcin K inhibited TNF-α, IL-1β, and IL-8 in RA synovial fibroblasts, blocked VCAM-1-mediated monocyte adhesion to joint tissue, and inhibited VEGF-driven angiogenesis in RA cells. All three are cell-culture studies. Reishi has been tested in two rat arthritis models — a 2024 nanogel study and a 2023 polysaccharide peptide study acting through NF-κB and MAPK inactivation. In humans, the single randomized trial of a reishi-containing formula did not meet its primary endpoint.

Can mushrooms help with multiple sclerosis?

No human trial has tested mushroom compounds in people with MS, so there is no evidence that they help. Preclinical research suggests possible myelin-protective properties: a 2022 animal study found that multiple mushroom species suppressed demyelination and motor dysfunction in mice treated with a myelin-destroying compound (the cuprizone model), and a 2025 review identified neuroprotective, anti-inflammatory, and immunomodulatory mechanisms as potentially relevant to MS. The cuprizone model works through toxic rather than immune-mediated myelin damage, so it captures only some features of human MS.

Is reishi mushroom good for lupus?

There is no human trial of reishi in lupus, so this cannot be answered from patient data. In mouse lupus models, a combination of reishi and San Miao San increased CD4+CD25+Foxp3+ regulatory T cell percentages in spleen, thymus, and blood, raised the regulatory-to-effector T cell ratio, and lowered IL-17A and anti-double-stranded-DNA antibodies. That is the direction a lupus therapy would need to move, but it was demonstrated in mice, using a two-herb combination rather than reishi alone. People with lupus on immunosuppressive medication should disclose any supplement use to their specialist before taking it.

Did reishi lower inflammation in rheumatoid arthritis patients?

Only in a narrow and specific sense. In the human trial and its companion immunology paper, plasma concentrations of IL-18, IP-10, MCP-1, MIG, and RANTES were unchanged after 8 and 24 weeks, and lymphocyte counts and ratios did not differ between groups. What did differ was the percentage change in ex vivo-induced IL-18 — IL-18 produced by patients' cells when stimulated in the laboratory, not IL-18 circulating in the blood. The trial authors explicitly stated that no significant anti-inflammatory or immunomodulating effect could be demonstrated.

What mushroom compounds help with RA joint inflammation?

Antcin K from Antrodia cinnamomea is the most specifically studied mushroom compound for RA inflammation in the current research literature. In cell studies it inhibited the three main pro-inflammatory cytokines in RA (TNF-α, IL-1β, IL-8), blocked immune cell adhesion to synovial tissue, and inhibited the angiogenesis that enables destructive tissue growth in RA joints. All Antcin K findings are from cell culture — there is no animal or human data for it. Reishi (Ganoderma lucidum) has been studied in two rat arthritis models and in one human trial that did not meet its primary endpoint.

Are there studies on mushrooms and autoimmune diseases?

Yes, but almost all are at an early stage. For rheumatoid arthritis, the laboratory work covers Antcin K across three separate mechanisms, plus two rat models of reishi, plus one randomized human trial that missed its primary endpoint. For lupus, animal studies cover Antrodia camphorata mycelial extract's effect on kidney inflammation and a reishi formula's effect on regulatory T cell ratios. For multiple sclerosis, a 2022 animal study showed demyelination suppression and a 2025 review synthesized the mechanistic evidence. Outside these three conditions, a 2015 study showed Antrodia cinnamomea inhibiting Th17 differentiation in a psoriasis model, which supports the shared-pathway argument.

Sources & References

1. 1RTHM-00206·Chang, Jia-Ming et al. (2011). “An Extract of Antrodia camphorata Mycelia Attenuates the Progression of Nephritis in Systemic Lupus Erythematosus-Prone NZB/W F1 Mice..” Evidence-based complementary and alternative medicine : eCAM.Study breakdown →PubMed →↩
2. 2RTHM-00578·Bhardwaj, Neha et al. (2014). “Suppression of inflammatory and allergic responses by pharmacologically potent fungus Ganoderma lucidum..” Recent patents on inflammation & allergy drug discovery.Study breakdown →PubMed →↩
3. 3RTHM-00670·Achudhan, David et al. (2021). “Antcin K Inhibits TNF-α, IL-1β and IL-8 Expression in Synovial Fibroblasts and Ameliorates Cartilage Degradation: Implications for the Treatment of Rheumatoid Arthritis..” Frontiers in immunology.Study breakdown →PubMed →↩
4. 4RTHM-00738·Achudhan, David et al. (2022). “Antcin K inhibits VCAM-1-dependent monocyte adhesion in human rheumatoid arthritis synovial fibroblasts..” Food & nutrition research.Study breakdown →PubMed →↩
5. 5RTHM-00739·Achudhan, David et al. (2022). “Antcin K inhibits VEGF-dependent angiogenesis in human rheumatoid arthritis synovial fibroblasts..” Journal of food biochemistry.Study breakdown →PubMed →↩
6. 6RTHM-01637·Yamashina, Kota et al. (2022). “Suppressive Effect of Fruiting Bodies of Medicinal Mushrooms on Demyelination and Motor Dysfunction in a Cuprizone-Induced Multiple Sclerosis Mouse Model..” International journal of medicinal mushrooms.Study breakdown →PubMed →↩
7. 7RTHM-01974·Ratnaningtyas, Nuniek Ina et al. (2024). “Lingzhi or Reishi Medicinal Mushroom Ganoderma lucidum (Agaricomycetes) Nanogel in a Complete Freund's Adjuvant-Induced Rheumatoid Arthritis Rat Model: Anti-Arthritic, Anti-Inflammatory, and Antioxidative Activity..” International journal of medicinal mushrooms.Study breakdown →PubMed →↩
8. 8RTHM-02163·Pourmohammadi, Golchehr et al. (2025). “New approach of using medicinal mushrooms for managing and curing multiple sclerosis..” Fitoterapia.Study breakdown →PubMed →↩
9. 9RTHM-02315·Li, Edmund K et al. (2007). “Safety and efficacy of Ganoderma lucidum (lingzhi) and San Miao San supplementation in patients with rheumatoid arthritis: a double-blind, randomized, placebo-controlled pilot trial..” Arthritis and rheumatism.Study breakdown →PubMed →↩
10. 10RTHM-02314·Bao, Yi Xi et al. (2006). “Immunomodulatory effects of lingzhi and san-miao-san supplementation on patients with rheumatoid arthritis..” Immunopharmacology and immunotoxicology.Study breakdown →PubMed →↩
11. 11RTHM-00766·Cai, Zhe et al. (2016). “Anti-inflammatory activities of Ganoderma lucidum (Lingzhi) and San-Miao-San supplements in MRL/lpr mice for the treatment of systemic lupus erythematosus..” Chinese medicine.Study breakdown →PubMed →↩
12. 12RTHM-00389·Li, Ming-Han et al. (2015). “Antrodia cinnamomea Extract Inhibits Th17 Cell Differentiation and Ameliorates Imiquimod-Induced Psoriasiform Skin Inflammation..” The American journal of Chinese medicine.Study breakdown →PubMed →↩
13. 13RTHM-01751·Meng, Meng et al. (2023). “Ganoderma lucidum polysaccharide peptide (GLPP) attenuates rheumatic arthritis in rats through inactivating NF-κB and MAPK signaling pathways..” Phytomedicine : international journal of phytotherapy and phytopharmacology.Study breakdown →PubMed →↩